Crossmark

Refining existing knowledge and management of bladder cancer

Crossref DOI link: https://doi.org/10.1038/s41585-018-0137-3

Published Online: 2018-12-21

Published Print: 2019-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Teo, Min Yuen

Rosenberg, Jonathan E.
License Information

Text and Data Mining valid from 2018-12-21
More Information

Article History

First Online: 21 December 2018

Competing interests

: J.E.R. has received consulting fees from Genentech/Roche, AstraZeneca, Bristol-Myers Squibb, Seattle Genetics, Merck, Bayer, EMD Serono, Astellas, Sensiei Biotherapeutics, Pharmacyclics, Inovio, Gritstone, Western Oncolytics, Bioclin, QED Therapeutics, Adicet Bio, Fortress Biotech and Mirati Research; funding (for industry trials) from Genentech/Roche, Astellas and Bayer; and research funding (investigator-initiated trials) from Novartis and Genentech/Roche. M.Y.T. has received research funding (investigator-initiated trial) from Bristol-Myers Squibb and funding (for industry trials) from Clovis Oncology.